---
title: "Policy Tailwinds Shift Capital to Hong Kong's Overlooked Infrastructure and Tech"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300409173.md"
description: "June saw HKD 1.5 billion flow into Hang Seng Tech ETFs as infrastructure policy gains traction. Shenzhen Expressway extended concessions, Fosun Pharma closed European deals, and JW Therapeutics gained CAR-T approval amid selective cyclical strength."
datetime: "2026-09-29T09:15:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300409173.md)
  - [en](https://longbridge.com/en/news/300409173.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300409173.md)
generator: "portal-rs"
---

# Policy Tailwinds Shift Capital to Hong Kong's Overlooked Infrastructure and Tech

China's infrastructure stimulus is quietly reshaping investor interest in overlooked Hong Kong equities. Shenzhen Expressway (1164.HK) extended its core route concessions through 2040 in June, marking a rare operational win for traditional infrastructure plays. Fosun Pharma (2915.HK) accelerated overseas acquisitions with a European biotech deal finalized in April, while JW Therapeutics (2533.HK) secured CAR-T therapy approval in May—a critical milestone for the beleaguered biotech sector.

Hang Seng Tech ETFs are seeing meaningful capital shifts. CSOP's offering (7233.HK) and Yinhua's counterpart (3466.HK) collectively pulled in over HKD 1.5 billion during June's market stabilization. China High Speed Transmission (0696.HK) reported 18% YoY growth in wind turbine component orders for Q2, aligning with mainland renewable energy targets. Kangzhe Pharmaceuticals (1815.HK) expanded Southeast Asian distribution channels, pushing international revenue past 30% of total.

Cyclical names show selective strength: Chongqing Iron & Steel (0434.HK) partnered with Baowu Steel on production optimization in May, and Dongzheng Auto Finance (0189.HK) saw new energy vehicle loans climb to 35% of its portfolio. I-Mab Biopharma (2715.HK) advanced two clinical programs with promising interim data, though commercialization timelines remain fluid. These developments reflect a broader pattern of policy-driven capital rotation into undervalued segments.

### Related Stocks

- [00189.HK](https://longbridge.com/en/quote/00189.HK.md)
- [00434.HK](https://longbridge.com/en/quote/00434.HK.md)
- [00696.HK](https://longbridge.com/en/quote/00696.HK.md)
- [01164.HK](https://longbridge.com/en/quote/01164.HK.md)
- [01815.HK](https://longbridge.com/en/quote/01815.HK.md)
- [02533.HK](https://longbridge.com/en/quote/02533.HK.md)
- [02715.HK](https://longbridge.com/en/quote/02715.HK.md)
- [02915.HK](https://longbridge.com/en/quote/02915.HK.md)
- [03466.HK](https://longbridge.com/en/quote/03466.HK.md)
- [07233.HK](https://longbridge.com/en/quote/07233.HK.md)

## Related News & Research

- [Dongyue Group Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation](https://longbridge.com/en/news/306254778.md)
- [Dongyue Group Reports Share Buyback for Cancellation in HKEX Next-Day Disclosure](https://longbridge.com/en/news/306104780.md)
- [Mount Everest Gold Reports Share Capital Increase of 277,000,000 New Shares in HKEX Next Day Disclosure](https://longbridge.com/en/news/305638188.md)
- [Mount Everest Gold Raises HK$ 443.2 Million in Share Placement](https://longbridge.com/en/news/305434838.md)
- [Dongyue Group Files HKEX Return Disclosing Share Buyback for Cancellation](https://longbridge.com/en/news/304992669.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**